Literature DB >> 1569174

Immunocytochemical localization of transforming growth factors (TGFs) TGF-alpha and TGF-beta in human ovarian tissues.

N Chegini1, R S Williams.   

Abstract

Light microscopic immunocytochemical technique was utilized in order to elucidate the presence and cellular distribution of transforming growth factors alpha and beta (TGF-alpha and TGF-beta) in human ovarian tissues in different reproductive states using polyclonal antibodies to TGF-alpha and TGF-beta. The results indicated that the ovarian tissue immunostained for both TGF-alpha and TGF-beta. The immunostaining for TGF-alpha was associated with oocytes in the primary follicles, granulosa and theca cell layers, as well as small and large luteal cells. The granulosa cell layers in the small follicles were immunostained for TGF-alpha, but there was very little staining association to the theca cell layers. However, the immunostaining intensity increased in both granulosa and theca cell layers as the size of the follicles increased. The ovarian stroma cells always showed moderate immunostaining. In luteal tissue, both small and large luteal cells immunostained for TGF-alpha and the intensity was similar in both cell types. The immunostaining intensity was similar in both early and midluteal phases and was less than that seen in the granulosa-theca cell layers of the large follicles, and decreased in the late luteal phase. Both corpora albicans and ectopic pregnancy corpora lutea showed a weak immunostaining. Immunostaining of ovarian tissues for TGF-beta indicated that the oocytes of the small preantral follicles stained faintly in the cytoplasm; however, they stained strongly around the nuclear periphery. In small, medium, and large follicles granulosa and theca cell layers immunostained with similar intensity for TGF-beta and its intensity increased with follicular size. The ovarian stroma cells also immunostained for TGF-beta, but with a moderate to low intensity compared with other regions. In luteal tissue, both small and large luteal cells immunostained for TGF-beta and its intensity was similar in early and midluteal phases and reduced during the late luteal phase. This immunostaining was reduced as compared to the granulosa-theca cell layers of the follicles. Corpora albicans and ectopic pregnancy corpora lutea also immunostained for TGF-beta; however, the immunostaining intensity was lower than that seen in luteal tissues of early, mid, or late luteal phases. There was strong immunostaining of the luteal fibroblasts and, interestingly, in small and medium size arterioles; endothelial and smooth muscle cells also immunostained strongly for TGF-beta, whereas the large arterioles showed very little or no immunostaining.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569174     DOI: 10.1210/jcem.74.5.1569174

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Immunolocalization of transforming growth factor alpha in normal human tissues.

Authors:  M E Christensen; S S Poulsen
Journal:  Histochem Cell Biol       Date:  1996-05       Impact factor: 4.304

2.  A proteomic analysis of human follicular fluid: comparison between fertilized oocytes and non-fertilized oocytes in the same patient.

Authors:  Akira Iwase; Hiroharu Kobayashi; Maki Goto; Tatsuo Nakahara; Tomoko Nakamura; Mika Kondo; Yoshinari Nagatomo; Tomomi Kotani; Fumitaka Kikkawa
Journal:  J Assist Reprod Genet       Date:  2013-07-26       Impact factor: 3.412

3.  Transforming growth factor-α inhibition of luteinizing hormone-stimulated androgen production by ovarian theca-interstitial cells: mechanism of action.

Authors:  S R Weitsman; D A Magoffin
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

4.  Epidermal growth factor (EGF) receptor localization in cultured human granulosa lutein cells and the stimulation of progesterone production by EGF and transforming growth factor-alpha (TGF-alpha).

Authors:  F R Tekpetey; S A Daniel; A Yuzpe
Journal:  J Assist Reprod Genet       Date:  1995-11       Impact factor: 3.412

5.  Effects of nerve growth factor (NGF) on blood vessels area and expression of the angiogenic factors VEGF and TGFbeta1 in the rat ovary.

Authors:  Marcela Julio-Pieper; Hernán E Lara; Javier A Bravo; Carmen Romero
Journal:  Reprod Biol Endocrinol       Date:  2006-11-10       Impact factor: 5.211

6.  The role of transforming growth factor-beta (TGF-beta) during ovarian follicular development in sheep.

Authors:  Jennifer L Juengel; Adrian H Bibby; Karen L Reader; Stan Lun; Laurel D Quirke; Lisa J Haydon; Kenneth P McNatty
Journal:  Reprod Biol Endocrinol       Date:  2004-11-25       Impact factor: 5.211

7.  TGF-β1 Up-Regulates Connective Tissue Growth Factor Expression in Human Granulosa Cells through Smad and ERK1/2 Signaling Pathways.

Authors:  Jung-Chien Cheng; Hsun-Ming Chang; Lanlan Fang; Ying-Pu Sun; Peter C K Leung
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

8.  Prostaglandin F-induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity.

Authors:  Alba Jiménez-Segovia; Alba Mota; Alejandro Rojo-Sebastián; Beatriz Barrocal; Angela Rynne-Vidal; María-Laura García-Bermejo; Raquel Gómez-Bris; Lukas J A C Hawinkels; Pilar Sandoval; Ramon Garcia-Escudero; Manuel López-Cabrera; Gema Moreno-Bueno; Manuel Fresno; Konstantinos Stamatakis
Journal:  Neoplasia       Date:  2019-11-14       Impact factor: 5.715

Review 9.  The Many Microenvironments of Ovarian Cancer.

Authors:  Hannah M Micek; Mike R Visetsouk; Andrew J Fleszar; Pamela K Kreeger
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome.

Authors:  Lanlan Fang; Yiran Li; Sijia Wang; Yuxi Li; Hsun-Ming Chang; Yuyin Yi; Yang Yan; Avinash Thakur; Peter C K Leung; Jung-Chien Cheng; Ying-Pu Sun
Journal:  Exp Mol Med       Date:  2020-03-10       Impact factor: 8.718

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.